Targeting prefrontal cortical dopamine D1 and N-methyl-D-aspartate receptor interactions in schizophrenia treatment

被引:50
|
作者
Yang, CR [1 ]
Chen, L
机构
[1] Eli Lilly & Co, Corp Ctr, Neurosci Discovery, Indianapolis, IN 46285 USA
[2] Nanjing Univ, Lab Actupuncture & Pharmacol, Nanjing 210008, Peoples R China
来源
NEUROSCIENTIST | 2005年 / 11卷 / 05期
关键词
dopamine; glutamate; schizophrenia; glycine transporter-1; D1; receptor; glycine; stepholidine; allosteric modulation;
D O I
10.1177/1073858405279692
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The prefrontal cortex plays a principal role in higher cognition and particularly in the fast online manipulation of appropriate information to guide forthcoming behavior. Dysfunction of this process represents a main feature in the pathophysiology of schizophrenia. Both dopamine D1 and N-methyl-D-aspartate (NMDA) receptors in the prefrontal cortex play a critical role in synaptic plasticity, memory mechanisms, and cognition. Recent data have shown that D1 and NMDA receptors interact bidirectionally and may greatly influence the output of the prefrontal cortex. Hypofunction of these receptor systems in the prefrontal cortex is found in schizophrenia. This review attempts to summarize some of the latest findings on the cellular mechanisms that underlie D1-NMDA receptor interactions. These findings have provided potential therapeutic strategies that aim to functionally up-regulate D1 and/or NMDA receptor safely via selective activation of D1 receptors or coagonist activation of NMDA receptors through blockade of the glycine transporter-1.
引用
收藏
页码:452 / 470
页数:19
相关论文
共 50 条
  • [21] N-Methyl-D-aspartate receptor autoantibodies in schizophrenia and affective disorders
    Steiner, Johann
    Bogerts, Bernhard
    SCHIZOPHRENIA RESEARCH, 2015, 162 (1-3) : 291 - 291
  • [22] Molecular evidence of N-methyl-D-aspartate receptor hypofunction in schizophrenia
    Weickert, C. S.
    Fung, S. J.
    Catts, V. S.
    Schofield, P. R.
    Allen, K. M.
    Moore, L. T.
    Newell, K. A.
    Pellen, D.
    Huang, X-F
    Catts, S. V.
    Weickert, T. W.
    MOLECULAR PSYCHIATRY, 2013, 18 (11) : 1185 - 1192
  • [23] Interactions between dopamine transporter and N-methyl-D-aspartate receptor-related amino acids on cognitive impairments in schizophrenia
    Chou, Y. -H.
    EUROPEAN PSYCHIATRY, 2023, 66 : S497 - S497
  • [24] Interactions between dopamine transporter and N-methyl-D-aspartate receptor-related amino acids on cognitive impairments in schizophrenia
    Yang, Kai-Chun
    Chen, Yen-Yu
    Liu, Mu-N
    Yang, Bang-Hung
    Chou, Yuan-Hwa
    SCHIZOPHRENIA RESEARCH, 2022, 248 : 263 - 270
  • [25] GSK-3β Interacts with Dopamine D1 Receptor to Regulate Receptor Function: Implication for Prefrontal Cortical D1 Receptor Dysfunction in Schizophrenia
    Wang, Jing-Ru
    Sun, Pei-Hua
    Ren, Zhao-Xiang
    Meltzer, Herbert Y.
    Zhen, Xue-Chu
    CNS NEUROSCIENCE & THERAPEUTICS, 2017, 23 (02) : 174 - 187
  • [26] Apolipoprotein E receptor 2 interactions with the N-methyl-D-aspartate receptor
    Hoe, HS
    Pocivavsek, A
    Chakraborty, G
    Fu, ZY
    Vicini, S
    Ehlers, MD
    Rebeck, GW
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (06) : 3425 - 3431
  • [27] THE N-METHYL-D-ASPARTATE RECEPTOR COMPLEX
    WILLIAMS, M
    LOO, PA
    MURPHY, DE
    BRAUNWALDER, AF
    JARVIS, MF
    SILLS, MA
    JOURNAL OF RECEPTOR RESEARCH, 1988, 8 (1-4): : 195 - 203
  • [28] TEMPERATURE DEPENDENCE OF N-METHYL-D-ASPARTATE RECEPTOR CHANNELS AND N-METHYL-D-ASPARTATE RECEPTOR EXCITATORY POSTSYNAPTIC CURRENTS
    Korinek, M.
    Sedlacek, M.
    Cais, O.
    Dittert, I.
    Vyklicky, L., Jr.
    NEUROSCIENCE, 2010, 165 (03) : 736 - 748
  • [29] Targeting Peripheral N-Methyl-D-Aspartate Receptor (NMDAR): A Novel Strategy for the Treatment of Migraine
    Kalatharan, Veberka
    Al-Karagholi, Mohammad Al-Mahdi
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (06)
  • [30] Prefrontal dopamine transmission in schizophrenia:: Is D1 receptor A relevant biomarker?
    Abi-Dargham, A
    Guo, N
    Narendran, R
    Hwang, D
    Ekelund, J
    Guillin, O
    Martinez, D
    Frankle, G
    Laruelle, M
    BEHAVIOURAL PHARMACOLOGY, 2005, 16 : S13 - S13